Compare CXE & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXE | VRCA |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 137.3M |
| IPO Year | N/A | 2018 |
| Metric | CXE | VRCA |
|---|---|---|
| Price | $3.65 | $6.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 92.7K | 46.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | $52.14 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $3.40 | $0.52 |
| 52 Week High | $3.88 | $9.82 |
| Indicator | CXE | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 50.43 |
| Support Level | $3.63 | $6.15 |
| Resistance Level | $3.78 | $6.40 |
| Average True Range (ATR) | 0.03 | 0.49 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 44.40 | 57.58 |
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.